{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-041367","form_type":"8-K","ticker":null,"cik":"0001779020","company_name":"Danimer Scientific, Inc.","filed_at":"2025-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.822518+00:00","generated_at":"2026-05-24T14:06:42.229391+00:00","sec_items":["1.03","2.04","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Danimer Scientific files Chapter 11 with $400.8M debt, plans winddown and sale","bullets":["Filed voluntary Chapter 11 petitions on March 18, 2025 in Delaware Bankruptcy Court.","Approximately $400.8M aggregate debt accelerated, including $211.4M convertible notes due 2026 and $128.6M Jefferies loan.","Seeking DIP facility of $1M interim (up to $3M final) plus $12M roll-up from existing super senior note.","Debtors plan orderly winddown of operations while pursuing sale of manufacturing facilities.","Company warns common stock holders face loss; filed NOL motion to restrict stock trades to preserve tax attributes."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-041367","json":"https://secwatch.observer/filing/0000950170-25-041367.json","markdown":"https://secwatch.observer/filing/0000950170-25-041367.md","text":"https://secwatch.observer/filing/0000950170-25-041367.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1779020/000095017025041367/0000950170-25-041367-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1779020/000095017025041367/dnmr-20250318.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T14:06:42.229391+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"08976ac2928bd8600b743d6d7971f1c381f88c15","claim":"Danimer Scientific, Inc. faced acceleration on loan of $24.7 million with HRV SUB-CDE 45, L.L.C., AMCREF FUND 76, LLC, ST CDE LXXXIII, LLC, and CDVCA 23, LLC.","evidence_excerpt":"The QLICI Loan and Security Agreement, dated August 23, 2022, by and between Meredian Bioplastics, Inc., as borrower, and HRV SUB-CDE 45, L.L.C., AMCREF FUND 76, LLC, ST CDE LXXXIII, LLC, and CDVCA 23, LLC, as lenders, as the same has been amended, supplemented or otherwise modified from time to time, and the approximately $24.7 million outstanding thereunder","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1779020/000095017025041367/0000950170-25-041367-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$24.7 million"},{"label":"Counterparty","value":"HRV SUB-CDE 45, L.L.C., AMCREF FUND 76, LLC, ST CDE LXXXIII, LLC, and CDVCA 23, LLC"},{"label":"Event","value":"acceleration"}],"fact_type":"debt_financing"},{"claim_id":"1ae3228c2d57be9a1bcf058de463c61b9d38a1cd","claim":"Danimer Scientific, Inc. faced acceleration on credit facility of $128.6 million with Jefferies Funding LLC.","evidence_excerpt":"LLC, as lender, and U.S. Bank Trust Company, National Association, as the same has been amended, supplemented or otherwise modified from time to time, and the approximately $128.6 million outstanding thereunder; • The Super Senior Secured Uninsured Promissory Note, dated as of December 17, 2024, by and among the Company, as issuer, certain of the Company’s","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1779020/000095017025041367/0000950170-25-041367-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Principal","value":"$128.6 million"},{"label":"Counterparty","value":"Jefferies Funding LLC"},{"label":"Event","value":"acceleration"}],"fact_type":"debt_financing"},{"claim_id":"9624b4163d3413be3c0f0d63c77dc3281fc6b524","claim":"Danimer Scientific, Inc. faced acceleration on senior notes of $15.1 million with Jefferies Capital Services, LLC, Riva Ridge Master Fund, Ltd. and BPI Credit 6, LLC.","evidence_excerpt":"The Super Senior Secured Uninsured Promissory Note, dated as of December 17, 2024, by and among the Company, as issuer, certain of the Company’s subsidiaries, as guarantors, and Jefferies Capital Services, LLC, Riva Ridge Master Fund, Ltd. and BPI Credit 6, LLC, as payees, as the same has been amended, supplemented or otherwise modified from time to time, and the approximately $15.1 million outstanding thereunder","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1779020/000095017025041367/0000950170-25-041367-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"senior notes"},{"label":"Principal","value":"$15.1 million"},{"label":"Counterparty","value":"Jefferies Capital Services, LLC, Riva Ridge Master Fund, Ltd. and BPI Credit 6, LLC"},{"label":"Event","value":"acceleration"}],"fact_type":"debt_financing"},{"claim_id":"ce9bdfacf4325d75427ae387faaae265f7df9ad2","claim":"Danimer Scientific, Inc. faced acceleration on convertible notes of $211.4 million with U.S. Bank, National Association at 3.250% maturing 2026.","evidence_excerpt":"The Indenture, dated as of December 21, 2021, by and among the Company, as issuer, and U.S. Bank, National Association, as trustee, and the approximately $211.4 million in aggregate outstanding principal amount of 3.250% Convertible Senior Notes due 2026 issued thereunder","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1779020/000095017025041367/0000950170-25-041367-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$211.4 million"},{"label":"Counterparty","value":"U.S. Bank, National Association"},{"label":"Rate","value":"3.250%"},{"label":"Maturity","value":"2026"},{"label":"Event","value":"acceleration"}],"fact_type":"debt_financing"},{"claim_id":"6319af8ecfafeccef650641325fda33e5d212a7b","claim":"Danimer Scientific, Inc. entered chapter 11 in United States Bankruptcy Court for the District of Delaware (petition 2025-03-18).","evidence_excerpt":"On March 18, 2025 (the “Petition Date”), Danimer Scientific, Inc. (the “Company”) and its subsidiaries (together with the Company, the “Debtors”) filed voluntary petitions to commence proceedings under chapter 11 (the “Chapter 11 Cases”) of title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”).","evidence_source":"SEC 8-K Item 1.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1779020/000095017025041367/0000950170-25-041367-index.htm","confidence":0.9,"family_label":"Distress & Bankruptcy","details":[{"label":"Proceeding","value":"chapter 11"},{"label":"Court","value":"United States Bankruptcy Court for the District of Delaware"},{"label":"Petition","value":"2025-03-18"}],"fact_type":"distress_event"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}